Response to report in the New England Journal of Medicine regarding the use of rosiglitazone (AVANDIA) by people with type 2 diabetes

Source: Diabetes Australia

On 21st May 2007 the New England Journal of Medicine reported on a new analysis which highlighted the possibility of increased risk of heart attack (myocardial infarction and death from cardiovascular causes) through the use of rosiglitazone (AVANDIA) by people with type 2 diabetes.

Diabetes Australia is closely monitoring the situation. It is important to note that the report is based on a preliminary study, which by its design cannot be definitive. The authors of the recently published study themselves state that it has important limitations and the results have ‘considerable uncertainty about the magnitude of observed hazard’.

Diabetes management should be monitored and assessed on an individual basis through consultation between patient and doctor. However Diabetes Australia suggests that people with type 2 diabetes who take rosiglitazone (AVANDIA) should not stop using this medication until they have discussed their ongoing use of this medication individually with their GP or specialist. If a decision is then made to discontinue rosiglitazone (AVANDIA), alternative treatments to maintain diabetes control will need to be considered.

Read the rest of this entry »